Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy

References

• Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807–12.
   PubMed Web of Science ®Google Scholar
• Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue?Cancer Res 1986;46:467–73.
   PubMed Web of Science ®Google Scholar
• Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770–5.
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401–10.
   PubMed Web of Science ®Google Scholar
• Stoeltzing O, Ellis LM. The role of microvasculature in metastasis formation. In: Siemann DW, editor. Vascular- targeted therapies in oncology. Chichester: John Wiley & Sons, Ltd.; 2006. p. 31–62.
   Google Scholar
• Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11: 416–20.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520–39.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Website: www.cancer.gov/clinicaltrials.
   Google Scholar
• Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011;50:630–5.
   PubMed Web of Science ®Google Scholar
• Cao C, Wang J, Bunjhoo H, Xu Y, Fang H. Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials. Acta Oncol 2012;51:151–6.
   PubMed Web of Science ®Google Scholar
• Patterson DM, Rustin GJS. Vascular damaging agents. Clin Oncol 2007;19:443–56.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother Oncol 2000;57:5–12.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674–87.
   PubMed Web of Science ®Google Scholar
• Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141–8.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423–35.
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Onol 2011;29:2965–71.
   PubMed Web of Science ®Google Scholar
• Früh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, et al. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: A multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2013;14:34–9.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009;18:189–97.
   PubMed Web of Science ®Google Scholar
• Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 2012;18:1415–25.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980;6:1507–17.
   PubMed Web of Science ®Google Scholar
• Nielsen T, Murata R, Maxwell RJ, Stødkilde-Jørgensen H, Østergaard L, Horsman MR. Preclinical studies to predict the efficacy of the vascular changes induced by combretastatin A-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys 2008;70:859–66.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Nordsmark M, Khalil AA, Hill SA, Chaplin DJ, Siemann DW, et al. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol 1994;33:371–6.
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiother Oncol 2001; 60:155–61.
   Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001;156:503–9.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Combination of vascular targeting agents with thermal and radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:1518–23.
   PubMed Web of Science ®Google Scholar
• Murata R, Horsman MR. Tumour specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2004;20:393–404.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57:1047–55.
   PubMed Web of Science ®Google Scholar
• Bertelsen LB, Shen YY, Nielsen T, Stødkilde-Jørgensen H, Lloyd GK, Siemann DW, et al. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int J Radiat Biol 2011;87:1126–34.
   PubMed Web of Science ®Google Scholar
• Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005;11:835–42.
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, Dahl O. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother Oncol 2001; 61:313–20.
   PubMed Web of Science ®Google Scholar
• El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005;41: 799–806.
   PubMed Web of Science ®Google Scholar
• Zhao D, Jiang L, Hahn EW, Mason RP. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 2005;62:872–80.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996;12:779–89.
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001; 77:195–204.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard JThe effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998;42:895–8.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Wouters BG, Joiner MC, Overgaard J. The oxygen effect and fractionated radiotherapy. In: van der Kogel AJ, Joiner M, editors. Basic clinical radiobiology, 4th ed. Hodder Arnold: London; 2009. p 207–16.
   Google Scholar
• Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006;12:4090–4.
   PubMed Web of Science ®Google Scholar
• Folkes LK, Christlieb M, Madej E, Stratford MRL, Wardman P. Oxidative metabolism of combretastatin A-1 produces quinine intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol 2007;20:1885–94.
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Galappathi K, Mathiesen B, Ruud EBM. Fluctuating and diffusion limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 2007;13:1971–8.
   Google Scholar
• Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009;26:19–34.
   PubMed Web of Science ®Google Scholar
• Ellingsen C, Hompland T, Mathiesen B, Rofstad EK. Microenvironment-associated lymph node metastasis of human cervical carcinoma xenografts. Acta Oncol 2012;51:465–72.
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220–31.
   PubMed Web of Science ®Google Scholar
• Ebos JML, Lee CR, Cruz-Munoz W, Bjamason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232–9.
   PubMed Web of Science ®Google Scholar